𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of 5-fluorouracil/leucovorin for pediatric patients with malignant solid tumors

✍ Scribed by Charles B. Pratt; William H. Meyer; Nanna Howlett; Edwin C. Douglass; Laura C. Bowman; Debbie Poe; Kevin Mounce; Larry E. Kun; Janet A. Houghton

Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
512 KB
Volume
74
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase I study of a 120-hour continuous i
Phase I study of a 120-hour continuous intravenous infusion of 5-fluorouracil in pediatric patients with recurrent solid tumors: A pediatric oncology group study
✍ Green, Daniel M. ;Krischer, Jeffrey P. ;Bell, Beverly ;Brecher, Martin L. ;Cushi πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 340 KB

## Abstract To determine the maximum tolerated dose of 5‐fluorouracil administered as a 120‐hour continuous intravenous infusion to pediatric patients, we performed a phase I study using a starting dosage of 900 mg/m^2^/day. The maximum tolerated dosage (MTD) was 1,100 mg/m^2^/day. At this dosage l

5-fluorouracil and cis-platinum in the t
5-fluorouracil and cis-platinum in the treatment of refractory solid tumors: A pediatric oncology group phase I β€” II study
✍ Land, Vita J. ;Dyment, Paul G. ;Starling, Kenneth ;Strandjord, Sarah E. ;Chan, R πŸ“‚ Article πŸ“… 1981 πŸ› John Wiley and Sons 🌐 English βš– 189 KB

## Abstract Eleven patients with osteogenic sarcoma (9), Hodgkin disease (1), and mesenchymal sarcoma (1), were treated with 5‐fluorouracil (5‐FU) and cisplatin (DDP). Myelosuppression and vomiting of variable degrees occurred in all. No responses were seen.